SwanBio Therapeutics is researching and developing novel gene therapies for people living with neurological disorders. Historically, neurological disorders have been challenging targets for drug development. To create safe and effective drugs for diseases involving the spinal cord, highly targeted therapies and delivery strategies to deliver them to the nervous tissues are required. Through the use of adeno-associated viruses (AAVs), SwanBio is creating therapies that deliver genetic corrections to replace damaged games and treat the root cause of disease. This type of therapy has the potential to provide patients with durable responses rather than only symptom management. SwanBio’s lead program, SBT101, aims to treat patients with adrenomyeloneuropathy.

SwanBio Therapeutics

Founded: 2017
Location: Bala Cynwyd, PA
Employee range: 11 - 50
Clinical stage: Clin1
Therapy area: Adrenomyeloneuropathy
Drug types: NEU, GEN, RAR
Lead product: SBT101
Funding: $56M B May 2022; $52M A Apr 2020

Drug notes:

About:

Jobs: